ALG-1007
Dry Eye Disease (DED)
Pre-clinical/Phase 1Active
Key Facts
About Allegro Ophthalmics
Allegro Ophthalmics is a private, clinical-stage biotech developing a novel class of 'mitochondrial stabilizer' therapies for major ocular diseases. Its lead asset, risuteganib, has shown promise in Phase 2a for intermediate dry AMD and is now in Phase 2b/3 planning under an FDA Special Protocol Assessment (SPA), with a licensee advancing Phase 3 trials in China. The company's platform targets integrin dysregulation to address mitochondrial dysfunction and oxidative stress, aiming to provide treatment options for patients who inadequately respond to current therapies.
View full company profileTherapeutic Areas
Other Dry Eye Disease (DED) Drugs
| Drug | Company | Phase |
|---|---|---|
| Licaminlimab (OCS-02) | Oculis | Phase 2/3 |
| PRP/Excipient Formulation | ECI Therapeutics | Pre-clinical |
| SLG-100 | Selagine | Clinical Stage (Pilot trial completed) |
| Carragelose® Eyedrops | Unither Pharmaceuticals | Commercial (Out-licensing) |
| RO-7071759 | Rohto Pharmaceutical | Phase 2 |
| Urcosimod (OK-101) | OKYO Pharma | Phase 2 |